Skip Navigation
Megan McArdle

Megan McArdle - Megan McArdle is a senior editor for The Atlantic who writes about business and economics. She has worked at three start-ups, a consulting firm, an investment bank, a disaster recovery firm at Ground Zero, and The Economist. More

Megan was born and raised on the Upper West Side of Manhattan, and yes, she does enjoy her lattes, as well as the occasional extra-dry skim-milk cappuccino. Her checkered work history includes three start-ups, four years as a technology project manager for a boutique consulting firm, a summer as an associate at an investment bank, and a year spent as sort of an executive copy girl for one of the disaster-recovery firms at Ground Zero … all before the age of 30.

While working at Ground Zero, Megan started Live From the WTC, a blog focused on economics, business, and cooking. She may or may not have been the first major economics blogger, depending on whether we are allowed to throw outlying variables such as Brad Delong out of the set. From there it was but a few steps down the slippery slope to freelance journalism. She has worked in various capacities for The Economist, where she wrote about economics and oversaw the founding of Free Exchange, the magazine's economics blog. She has also maintained her own blog, Asymmetrical Information, which moved to The Atlantic, along with its owner, in August 2007.

Megan holds a bachelor's degree in English literature from the University of Pennsylvania and an M.B.A. from the University of Chicago. After a lifetime as a New Yorker, she now resides in northwest Washington, D.C., where she is still trying to figure out what one does with an apartment larger than 400 square feet.

Why Gene Sequences Don't Equal Cures

By Megan McArdle
Apr 5 2011, 2:34 PM ET Comment

One of the major disappointments of the new millennium so far has been the failure of genomics to yield promising new medical treatments. This was supposed to save pharma, and, not incidentally, us, by letting us read the very molecules where things first went wrong.  Cures for cancer!  No more diabetes!  Take that, Cystic Fibrosis!

But cures have not really been forthcoming, and a post by Derek Lowe suggests some of the reasons why:

A new study, one of those things that could only be done with modern sequencing techniques, has given us the hardest data yet on the genomic basis of cancerous cells. This massive effort completely sequenced the tumors from 50 different breast cancer patients, along with nearby healthy cells as controls for each case. 
Over 1700 mutations were found - but only three of them showed up in as many as 10% of the patients. The great majority were unique to each patient, and they were all over the place: deletions, frame shifts, translocations, what have you. The lead author of the study told Nature News that the results were "complex and somewhat alarming", and I second that, only pausing to drop the "somewhat". I add that qualification because these patients were already more homogeneous than the normal run of breast cancer cases - they were all estrogen-receptor positive, picked for trials of an aromatase inhibitor.
In retrospect, it's easy to develop a healthy skepticism about the possibilities of genomics--at least, the early stages that we're now in.  Sequencing the human genome isn't really like being able to read the assembly instructions for the human body.  The instructions are in a nucleic acid code that gets acted on by lots of different agents to turn them into a final product like a protein, and we don't really know the code yet.  Sequencing the human genome was more like getting an instruction manual for something important--in a dead language for which we have no Rosetta Stone.

But I didn't have that skepticism at the time, and neither did a lot of people in the biosciences.  The human body keeps turning out to be way more complicated than we hope or expect.




Presented by

More at The Atlantic

AIPAC's Push Toward War New Push Toward War With Iran
The Future of 'Glee': Reasons for Hope, Reasons for Dread What's Next For 'Glee'?
The Entrepreneur State: Safety Nets for Startups, Capitalism for Corporations Startup Nation: A New Economic Framework
Reward Good Food: Prince Charles on Healthy, Sustainable Farming The Future of Food
How the Stinking Rich Ate the Economy How the Stinking Rich Ate the Economy

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus
Special Report
The Next Global Economies Reuters The Next Global Economies
Lessons from the BRICs — and a look at which developing countries are on the rise. Read more ›
View All Correspondents

The Biggest Story in Photos

More From Carnival 2012

Feb 22, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)

Megan McArdle
from the Magazine

Why Companies Fail

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult…

The Graduates

Busted banking careers, crashed consultants, and shrunken incomes: the author attends her 10-year…

Romney’s Business

The Republican contender touts his business experience—but does it really matter?